Chemical screens identify drugs that enhance or mitigate cellular responses to antibody-toxin fusion proteins

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Antignani, Antonella ^a   Griner, Lesley Mathews ^b   Guha, Rajarshi ^b   Simon, Nathan ^a   Pasetto, Matteo ^a,c   Keller, Jonathan ^b   Huang, Manjie ^a   Angelus, Evan ^a   Pastan, Ira ^a   Ferrer, Marc ^b   FitzGerald, David J ^a   Thomas, Craig J ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 5 [2 (2,6 DIMETHYLMORPHOLINO) 4 MORPHOLINOPYRIDO[2,3 D]PYRIMIDIN 7 YL] 2 METHOXYBENZENEMETHANOL; ANTIBODY TOXIN FUSION PROTEIN; ANTINEOPLASTIC AGENT; AZD 8055; DANUSERTIB; EVEROLIMUS; GB83; GSK 1904529A; IMMUNOTOXIN; INITIATION FACTOR 4E BINDING PROTEIN 1; MIFEPRISTONE; NIGULDIPINE; NILOTINIB; OLAPARIB; PROTEIN SERINE THREONINE KINASE; S61 KINASE; SALINOMYCIN; SERDEMETAN; TORIN 1; UNCLASSIFIED DRUG; VERAPAMIL; WORTMANNIN; EXOTOXIN; HYBRID PROTEIN; MOLECULAR LIBRARY; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG POTENTIATION; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN SYNTHESIS; SURVIVAL; TUMOR VOLUME; ANIMAL; DISEASE MODEL; DRUG DEVELOPMENT; GENETICS; MOLECULAR LIBRARY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; EXOTOXINS; FEMALE; HUMANS; IMMUNOTOXINS; MICE; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; RECOMBINANT FUSION PROTEINS; SMALL MOLECULE LIBRARIES; TOXINS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84990946512     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0161415     Document Type: Article

References (39)

1. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012; 12(4): 278-87. doi: 10.1038/nrc3236 PMID: 22437872
2. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer. 2006; 6(7): 559-65. PMID: 16794638
3. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med. 2007; 58: 221-37. PMID: 17059365
4. Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. Journal of clinical oncology: Official journal of the American Society of Clinical Oncology. 2005; 23(27): 6719-29.
5. Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. Journal of clinical oncology: Official journal of the American Society of Clinical Oncology. 2009; 27(18): 2983-90.
6. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. Journal of clinical oncology: Official journal of the American Society of Clinical Oncology. 2012; 30(15): 1822-8.
7. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clinical cancer research: An official journal of the American Association for Cancer Research. 2007; 13(17): 5144-9.
8. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clinical cancer research: An official journal of the American Association for Cancer Research. 2009; 15(16): 5274-9.
9. Mathews Griner LA, Guha R, Shinn P, Young RM, Keller JM, Liu D, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111(6): 2349-54. doi: 10.1073/pnas.1311846111 PMID: 24469833
10. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362(24): 2251-9. doi: 10.1056/NEJMoa0912614 PMID: 20525993
11. Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007; 110(12): 4055-63. PMID: 17720881
12. Reichardt P, Montemurro M. Clinical experience to date with nilotinib in gastrointestinal stromal tumors. Semin Oncol. 2011; 38 Suppl 1: S20-7. doi: 10.1053/j.seminoncol.2011.01.015 PMID: 21419932
13. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009; 138(4): 645-59. doi: 10.1016/j. cell.2009.06.034 PMID: 19682730
14. King TD, Suto MJ, Li Y. The Wnt/beta-catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer. Journal of cellular biochemistry. 2012; 113(1): 13-8. doi: 10.1002/jcb.23350 PMID: 21898546
15. Callaway TR, Edrington TS, Rychlik JL, Genovese KJ, Poole TL, Jung YS, et al. Ionophores: Their use as ruminant growth promotants and impact on food safety. Current issues in intestinal microbiology. 2003; 4(2): 43-51. PMID: 14503688
16. Ortolani S, Ciccarese C, Cingarlini S, Tortora G, Massari F. Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives. Future Oncol. 2015; 11(12): 1809-28. doi: 10.2217/fon.15.81 PMID: 26075448
17. Steelman LS, Martelli AM, Cocco L, Libra M, Nicoletti F, Abrams SL, et al. The Therapeutic Potential of mTOR Inhibitors in Breast Cancer. Br J Clin Pharmacol. 2016.
18. Atkins MB, Yasothan U, Kirkpatrick P. Everolimus. Nature reviews Drug discovery. 2009; 8(7): 535-6. doi: 10.1038/nrd2924 PMID: 19568281
19. Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. The Biochemical journal. 2012; 441(1): 1-21. doi: 10.1042/BJ20110892 PMID: 22168436
20. Hara K, Yonezawa K, Kozlowski MT, Sugimoto T, Andrabi K, Weng QP, et al. Regulation of eIF-4E BP1 phosphorylation by mTOR. The Journal of biological chemistry. 1997; 272(42): 26457-63. PMID: 9334222
21. Andersson Y, Juell S, Fodstad O. Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin a immunotoxin. International journal of cancer Journal international du cancer. 2004; 112(3): 475-83. PMID: 15382075
22. Antignani A, Sarnovsky R, FitzGerald DJ. ABT-737 promotes the dislocation of ER luminal proteins to the cytosol, including pseudomonas exotoxin. Molecular cancer therapeutics. 2014; 13(6): 1655-63. doi: 10.1158/1535-7163.MCT-13-0998 PMID: 24739394
23. Kang SA, Pacold ME, Cervantes CL, Lim D, Lou HJ, Ottina K, et al. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science. 2013; 341(6144): 1236566. doi: 10.1126/science.1236566 PMID: 23888043
24. Turgeon Z, Jorgensen R, Visschedyk D, Edwards PR, Legree S, McGregor C, et al. Newly discovered and characterized antivirulence compounds inhibit bacterial mono-ADP-ribosyltransferase toxins. Antimicrob Agents Chemother. 2011; 55(3): 983-91. doi: 10.1128/AAC.01164-10 PMID: 21135177
25. Wei H, Xiang L, Wayne AS, Chertov O, FitzGerald DJ, Bera TK, et al. Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(18): 6898-903. doi: 10.1073/pnas. 1204523109 PMID: 22509046
26. Simon NC, Aktories K, Barbieri JT. Novel bacterial ADP-ribosylating toxins: structure and function. Nature reviews Microbiology. 2014; 12(9): 599-611. doi: 10.1038/nrmicro3310 PMID: 25023120
27. Deng Q, Barbieri JT. Molecular mechanisms of the cytotoxicity of ADP-ribosylating toxins. Annual review of microbiology. 2008; 62: 271-88. doi: 10.1146/annurev.micro.62.081307.162848 PMID: 18785839
28. Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clinical cancer research: An official journal of the American Association for Cancer Research. 2010; 16(6): 1894-903.
29. Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, et al. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer. 2014; 120: 3311-9. doi: 10.1002/cncr.28875 PMID: 24989332
30. Traini R, Ben-Josef G, Pastrana DV, Moskatel E, Sharma AK, Antignani A, et al. ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxinbased proteins to the cell cytosol. Molecular cancer therapeutics. 2010; 9(7): 2007-15. doi: 10.1158/1535-7163.MCT-10-0257 PMID: 20587662
31. Du X, Xiang L, Mackall C, Pastan I. Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody. Clinical cancer research: An official journal of the American Association for Cancer Research. 2011; 17(18): 5926-34.
32. Mattoo AR, FitzGerald DJ.combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines. International journal of cancer Journal international du cancer. 2013; 132(4): 978-87. doi: 10.1002/ijc.27732 PMID: 22821746
33. Mattoo AR, Pastan I, Fitzgerald D.combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P. PloS one. 2013; 8(10): e75576. doi: 10.1371/journal.pone.0075576 PMID: 24130723
34. Hollevoet K, Antignani A, Fitzgerald DJ, Pastan I.combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells. Journal of immunotherapy. 2014; 37(1): 8-15. doi: 10.1097/CJI.0000000000000010 PMID: 24316551
35. Pasetto M, Antignani A, Ormanoglu P, Buehler E, Guha R, Pastan I, et al. Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxinmediated cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America. 2015; 112(10): E1135-42. doi: 10.1073/pnas.1501958112 PMID: 25713356
36. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, et al.comprehensive analysis of kinase inhibitor selectivity. Nature biotechnology. 2011; 29(11): 1046-51. doi: 10.1038/nbt.1990 PMID: 22037378
37. Ali-Rahmani F, FitzGerald DJ, Martin S, Patel P, Prunotto M, Ormanoglu P, et al. Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1. Cancer research. 2015; 76: 1560-8. doi: 10.1158/0008-5472.CAN-15-2401 PMID: 26719540
38. Onda M. Recombinant immunotoxins with low endotoxins for clinical and animal studies. Methods Mol Biol. 2012; 907: 627-43. doi: 10.1007/978-1-61779-974-7-35 PMID: 22907377
39. Guha R, Mathews Griner LA, Keller JM, Zhang X, Fitzgerald D, Antignani A, et al. Ranking Differential Drug Activities from Dose-Response Synthetic Lethality Screens. Journal of biomolecular screening. 2016;in press.